Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Pharmaceuticals (RCE) has reported positive data for its RECCE 327 antibiotic in a study treating the MRSA superbug
  • The antibiotic is aimed at bettering the treatment of burns and associated difficulties in closing wounds
  • Superbugs, such as MRSA, are a leading global cause of wound infections
  • The positive data showed RECCE significantly reduced bacteria and wounds in rats
  • In a separate 24-hour human skin model, results showed the antibiotic wasn’t irritating, even at high concentrations
  • The data will be presented to the ethics committee at an Australian hospital
  • The company is slightly down by 1.92 per cent, with shares trading for 25.5 cents each

Recce Pharmaceuticals has reported positive data in a rat topical burns model from an assessment of its lead compound RECCE 327.

The RECCE 327 antibiotic is aimed at addressing the unmet medical needs of burns treatment and associated difficulties in closing wounds.

RECCE 327 was previously awarded Qualified Infectious Disease Product designation by the U.S. Food and Drug Administration as a broad-spectrum antibiotic for intravenous indication against bacteraemia.

The study was undertaken with an established Australian teaching hospital, by an independent Contract Research Organisation (CRO).

Positive results showed RECCE 327 reduced bacterial load and enhanced wound closure.

Three groups of five rats showed RECCE 327 performed better than both the positive and negative controls.

Based on detailed results, day four is when wounds and bacterial loads significant reduced.

A separate human skin model showed the antibiotic wasn’t irritating, even at high concentrations.

“These data demonstrate that RECCE antibiotics has great potential to be applied in a broad range of clinical treatment settings,” Chairman Dr John Prendergast said.

The RECCE 327 lead compound is addressing the increasing threat of superbugs, such as Methicillin-Resistant Staphylococcus aureus (MRSA), that are resistant to antibiotics.

MRSA is a leading cause of wound infections globally. The U.S. alone reported 327,700 cases of MRSA in hospitalised patients and 10,600 estimated deaths in 2017.

The data from this study will be presented to the ethics committee at a hospital in Australia.

The company is slightly down by 1.92 per cent, with shares trading for 25.5 cents each at 12:44 pm AEDT.

RCE by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.